Although second-line generic antiretroviral drugs are of great value in developing countries, there are concerns regarding their quality. We studied a generic Lopinavir/ritonavir (200/50 mg; Arga-L, India) marketed in the Republic of Congo but not prequalified by WHO. Despite adequate quantitative and qualitative drug content, Arga-L had a bio-availablility of 10% compared with Kaletra. To avoid selection of drug-resistant HIV, rigorous pharmacological monitoring of generic drugs not prequalified by WHO must be a priority.
aHôpital FOCH, Suresnes, France
bFrance Expertise Internationale, Paris, France
cPharmaco-Toxicology Department, Hôpital Bichat, Paris, France.
Correspondence to Dr David Zucman Hôpital Foch, Service de médecine interne 92150 Suresnes France. E-mail: email@example.com
Received 23 September, 2013
Revised 28 November, 2013
Accepted 28 November, 2013